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Abstract
Objective: Rho-associated kinase (ROCK) is a key regulator of numerous pro-
cesses in multiple cell types relevant in stroke pathophysiology. ROCK inhibi-
tors have improved outcome in experimental models of acute ischemic or
hemorrhagic stroke. However, the relevant ROCK isoform (ROCK1 or ROCK2)
in acute stroke is not known. Methods: We characterized the pharmacodynamic
and pharmacokinetic proﬁle, and tested the efﬁcacy and safety of a novel selec-
tive ROCK2 inhibitor KD025 (formerly SLx-2119) in focal cerebral ischemia
models in mice. Results: KD025 dose-dependently reduced infarct volume after
transient middle cerebral artery occlusion. The therapeutic window was at
least 3 h from stroke onset, and the efﬁcacy was sustained for at least
4 weeks. KD025 was at least as efﬁcacious in aged, diabetic or female mice, as
in normal adult males. Concurrent treatment with atorvastatin was safe, but
not additive or synergistic. KD025 was also safe in a permanent ischemia
model, albeit with diminished efﬁcacy. As one mechanism of protection,
KD025 improved cortical perfusion in a distal middle cerebral artery occlusion
model, implicating enhanced collateral ﬂow. Unlike isoform-nonselective
ROCK inhibitors, KD025 did not cause signiﬁcant hypotension, a dose-limit-
ing side effect in acute ischemic stroke. Interpretation: Altogether, these data
show that KD025 is efﬁcacious and safe in acute focal cerebral ischemia in
mice, implicating ROCK2 as the relevant isoform in acute ischemic stroke.
Data suggest that selective ROCK2 inhibition has a favorable safety proﬁle to
facilitate clinical translation.
Introduction
Rho-associated protein kinase (ROCK) is an immediate
downstream effector for Rho GTPases, and a key regulator
of cytoskeletal dynamics, affecting numerous intracellular
processes such as cell motility and contraction. Many of
these cellular processes in vascular smooth muscle, endo-
thelial cells, neurons, glia, leukocytes, and platelets, are rel-
evant to the pathophysiology of stroke, making ROCK a
unique pleiotropic target with multiple potentially syner-
gistic mechanisms against ischemic injury.
1 ROCK has two
isoforms that differ in their expression patterns in various
tissues and cell types. Data suggest that ROCK2 is the pre-
dominant isoform expressed in neurons and vasculature.
2–4
ROCK has been targeted in neurovascular diseases such
as stroke for almost two decades. Small molecule ROCK
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5 anti-aggregant,
6 and anti-
inﬂammatory properties,
7 and reduce blood viscosity.
ROCK inhibition has also been shown to preserve blood–
brain barrier,
8 suppress apoptotic cell death in penumbra,
9
induce a pro-survival phenotype in astrocytes,
10 and to
improve neuroplasticity and recovery after spinal cord
injury.
11,12 Presumably a reﬂection of these converging
mechanisms, ROCK inhibitors have been uniformly efﬁca-
cious in various animal models of focal or global cerebral
ischemia, and reduced hemorrhage rate after thromboly-
sis.
1,13–15 However, available inhibitors do not distinguish
between the two isoforms, and can induce severe hypoten-
sion
5 as a dose-limiting side effect that might compromise
perfusion pressure and exacerbate ischemia in a subset of
acute stroke patients.
Therefore, we systematically investigated the efﬁcacy
and safety of a novel ROCK2-selective inhibitor KD025
in rodent models of focal cerebral ischemia toward
clinical translation. KD025 has 200-fold higher selectiv-
ity toward ROCK2 (IC50 105 nmol/L) compared with
ROCK1 (IC50 24 lmol/L).
16 Our results show that
selective ROCK2 inhibition is at least as efﬁcacious as
previously published isoform-nonselective inhibitors
such as hydroxyfasudil, and has a favorable safety pro-
ﬁle for clinical translation.
Methods
All experimental procedures were carried out in accor-
dance with the Guide for Care and Use of Laboratory
Animals (NIH Publication No. 85-23, 1996), and were
approved by the institutional review board (MGH Sub-
committee on Research Animal Care).
Study design
The clinical failure of many candidate drugs that showed
promise in acute experimental ischemia underscores the
importance of rigorous and comprehensive preclinical
testing along published guidelines and recommendations
by expert panels, including STAIR
17–19 and ARRIVE.
20
Therefore, we randomized and concealed allocation to
treatment arms, reported all mortality as well as attrition
due to other causes, and analyzed the data according to
intention-to-treat principle and did not exclude animals
showing signs of adverse effects such as vomiting or aspi-
ration. Multiple experimenters blinded to the treatment
group performed surgeries (J. H. L., Y. Z., Y. W., D.
v.B.) and assessed endpoints (M. B., J. H. L., A. D., Y.
W., D. v.B., Y. Z.). These experimenters did not adminis-
ter the treatments as KD025 could be distinguished from
the vehicle by its yellow color.
Animals and drug treatments
Young adult (C57BL/6, 2–3 months old, male 22–30 g,
female 16–23 g), aged (C57BL/6, 12 months old, 33–52 g),
or type 2 diabetic mice (db/db, B6.BKS(D)-Lepr
db/J, Jack-
son Laboratory; 2–3 months old, male, 33–50 g) were used
in all experiments. Only one animal was excluded due to
technical failure (hemorrhage during ﬁlament middle cere-
bral artery occlusion [fMCAO] in db/db mouse assigned to
the vehicle group). KD025 (formerly SLx-2119) was kindly
provided by Kadmon Corporation (New York, NY). Vehicle
(0.4% methylcellulose) or KD025 (100, 200 or 300 mg/kg)
was administered every 12 h via orogastric gavage. The
dosing paradigm was chosen based on the pharmacokinetic
proﬁle after oral administration in mice (see below). Ator-
vastatin (4 mg/mL) was dissolved in phosphate-buffered
saline (pH 7.4) containing 45% 3-hydroxypropyl-B-cyclo-
dextrin and 10% ethanol, and administered at a dose of
20 mg/kg per day as a single daily intraperitoneal injection
for 2 weeks as previously described.
21
ROCK1 versus ROCK2 selectivity
Recombinant ROCK1 and ROCK2 enzymes (truncated cat-
alytic domains) were purchased from Invitrogen (#PV3691
and PV3759, Carlsbad, CA) and enzymatic activity was
determined using [c
33P]ATP (5 mmol/L) and S6 kinase
substrate (17 mmol/L). The reaction was run for 45 min at
room temperature and was terminated by addition of phos-
phoric acid. [c
33P] phosphorylated S6 peptide was isolated
by membrane ﬁltration. The background was estimated by
running the reaction in the absence of enzyme and radio-
activity was assessed using a Microbeta Jet.
Pharmacokinetic studies
We measured plasma and brain concentrations of KD025
in male mice. Animals received 100 or 200 mg/kg KD025
twice a day for a total of ﬁve doses via orogastric gavage.
Blood and brain tissue were collected at different time
points after the last dose. For each time point, a different
group of mice was sacriﬁced (n = 5 each). Whole blood
was collected via jugular vein into K3 ethylenediaminete-
traacetic acid (EDTA) tubes, and centrifuged at 1000 g
for 3 min at 4°C. Immediately following blood collection,
mice were perfused with saline through the left ventricle
to clear intravascular blood, and brains were harvested.
All samples were stored at 80°C until analysis. Plasma
and tissue KD025 concentrations were measured using
high-resolution mass spectrometry (Thermo Fisher Q-Ex-
active; WIL Research Laboratories, Ashland, OH). Phar-
macokinetic parameters were calculated using PKSolver.
22
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of the terminal log-linear part of the concentration versus
time curve (kz) was calculated using the best-ﬁt method.
In addition, a one-compartmental analysis was performed
for zero- or ﬁrst-order kinetic models.
Recombinant ROCK1 and ROCK2 assays
Compound dilutions and reactions were performed in 96-
well polystyrene low-binding plates. Filtration was done in
96-well ﬁlter plates containing hydrophilic phospho-cellu-
lose cation exchanger membranes (Millipore, Bedford,
MA). Enzymatic activity of the recombinant ROCK1 and
ROCK2 (Invitrogen Corporation, Carlsbad, CA) was mea-
sured radiometrically in 50 lL of reaction mixture con-
taining assay buffer (50 mmol/L Tris, pH 7.5, 0.1 mmol/L
ethyleneglycoltetraacetic acid, 10 mmol/L magnesium ace-
tate and 1 mmol/L dithiothreitol). Long S6 peptide (KE
AKEKRQEQIAKRRRLSSLRASTSKSGGSQK, 30 lmol/L,
America Peptide Company, Sunnyvale, CA), ROCK
(4 mU per reaction) and ATP (10 lmol/L, Sigma-Aldrich,
St. Louis, MO; 1 lCi [c-
33P]ATP, Perkin Elmer, Waltham,
MA) and test compound were diluted to a ﬁnal dimethyl-
sulfoxide concentration of 1%. The reaction was incubated
for 45 min at room temperature and stopped with 25 lL
of 3% phosphoric acid. Phosphorylated long S6 peptide
was separated from unreacted [c-
33P]ATP by ﬁltration of
the quenched reaction contents through a P30 phospho-
cellulose ﬁlter plate using the Millipore Multiscreen
  vac-
uum manifold system (Millipore, Bedford, MA). Each
ﬁlter was washed three times with 75 lL of 75 mmol/L
phosphoric acid and one time with 30 lL of 100% metha-
nol. Filter plates were allowed to dry and 30 lL of Opti-
Phase ‘SuperMix’ scintillation ﬂuid (Perkin Elmer) was
added to each well.
33Phosphorous was quantiﬁed in an
I450 MicroBeta (Perkin Elmer) scintillation counter and
corrected by subtracting the radioactivity associated with
the background samples. Data were analyzed and
expressed as percent inhibition using the formula
((U  B)/(C  B)) 9 100 where U is the unknown value,
B is the average of staurosporine background wells, and C
is the average of control wells. Curve ﬁtting was performed
by GraphPad Prism software using sigmoidal dose-
response (variable slope) equation type analysis to generate
IC50 values. Ki values were calculated from an equation of
Ki = IC50/(1 + [S]/Km)), where [S] and Km are the concen-
tration of ATP and the Km value of ATP, respectively.
23
fMCAO and outcome assessments
Permanent or 1 h transient fMCAO was induced in mice
under isoﬂurane anesthesia (2.5% induction, 1.2% mainte-
nance, in 70% N2O/30% O2).
24 Intraluminal ﬁlament
(Doccol Corporation, Sharon, MA) was inserted through
the external carotid artery. Mice were allowed to awaken
from anesthesia after occlusion, and brieﬂy reanesthetized
for ﬁlament removal in the transient ischemia group.
Occlusion was conﬁrmed using laser Doppler ﬂowmetry
(Perimed, Ardmore, PA) over the core MCA territory. Rec-
tal temperature was controlled at 37°C by a servo-con-
trolled heating pad (FHC, Bowdoin, ME) during the
procedures. In all survival experiments, mice were placed
in a temperature-controlled incubator with easy access to
food and water after the procedure. Neurological deﬁcits
were assessed 48 h after reperfusion, using ﬁve-point grad-
ing: 0, normal; 1, forepaw monoparesis; 2, circling to one
side; 3, falling to one side; 4, no spontaneous walking and a
depressed level of consciousness. At 48 h after fMCAO,
infarct areas were measured on ten 1 mm-thick 2,3,5-tri-
phenyltetrazolium chloride (TTC)-stained coronal sections,
integrated to calculate the infarct volume, and corrected
for ischemic edema by subtracting the volume of ipsilateral
non-infarcted tissue from the contralateral hemisphere. In
addition, we assessed the incidence of hemorrhagic trans-
formation on the same TTC-stained sections using a semi-
quantitative grading system. In a separate group of mice,
we assessed outcome at 4 weeks. To enhance long-term
survival in this group, we administered intraperitoneal sal-
ine supplements (1 cc/day) and ampicillin (1 mg/day) for
up to 7 days. Tissue outcome was quantiﬁed by measuring
ipsilateral and contralateral hemispheric volumes and cal-
culating tissue loss and atrophy using coronal cryosections.
Neurological outcome was assessed weekly using the adhe-
sive removal test, where the time (sec) to remove a sticky
tape placed under the contralateral forepaw was quantiﬁed
(maximum 180 sec).
25,26
Distal middle cerebral artery occlusion
(dMCAO) and laser speckle ﬂowmetry
Mice (male, 25–30 g) were anesthetized with isoﬂurane as
above, intubated, and mechanically ventilated to maintain
arterial pH and blood gas values within normal range,
and femoral artery catheterized for continuous blood
pressure monitoring and blood sampling. Mice were then
placed in a stereotaxic frame, a temporal burr hole
(2 mm diameter) was drilled above the zygomatic arch,
and middle cerebral artery was occluded just distal to the
Table 1. ROCK1 versus ROCK2 selectivity of KD025 in comparison
with Y27632 and fasudil.
KD025 Y27632 Fasudil
ROCK2 Ki (nmol/L) 41  27 7  5 112  8
ROCK1 Ki (nmol/L) >10,000 68  2 145  7
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perfusion was imaged throughout the experiment using
laser speckle ﬂowmetry through intact skull.
27 Cerebral
blood ﬂow (CBF) changes were calculated for each pixel
relative to preischemic baseline, and the area of cortex
with residual CBF less than or equal to 20%, 21–30% and
31–40% was determined by thresholding.
Western blotting
Whole mouse brains were collected at 36 and 72 h after
1 h fMCAO. Brain and heart were homogenized in lysis
buffer (150 mmol/L NaCl, 50 mmol/L Tris pH 8.0,
0.5% NP-40, 50 mmol/L NaF, and 2 mmol/L EDTA,
protease inhibitor cocktail, HALT
TMphosphatase inhibitor
cocktail (Thermo Fisher Scientiﬁc, Waltham, MA) and
incubated on ice 20–30 min. After centrifugation at
14,000g for 10 min at 4°C, the supernatant was col-
lected. Protein concentration was determined with the
Bio-Rad DC protein assay reagent (Bio-Rad, Hercules,
CA). The protein lysates were separated on 4–15%
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) and transferred onto nitrocellulose
membrane. Blots were incubated with primary anti-p-
MYPT1
Thr696 (BD, San Diego, CA) antibody, followed
by horseradish peroxidase-conjugated secondary anti-
body, and visualized by enhanced chemiluminescence
reagents (ECL, Fisher Scientiﬁc, Waltham, MA).
Statistical analysis
Data were analyzed using Prism v 6.0b (GraphPad Soft-
ware, San Diego, CA), and expressed as median with in-
terquartile and full range (box and whisker plots) or
mean  standard error (SEM, line graphs, tables). Statis-
tical methods and group sizes are given in ﬁgure legends.
P < 0.05 was considered statistically signiﬁcant.
Results
ROCK1 versus ROCK2 selectivity
KD025 selectively inhibited ROCK2 with IC50 values
~60 nmol/L, but had little effect on ROCK1 enzymatic
activity at concentrations up to 10 lmol/L in a recom-
binant enzyme system (Fig. 1A). ROCK2 inhibition was
competitive with ATP (Fig. 1B). Table 1 shows the esti-
mated Ki values of KD025 compared to the non iso-
form selective inhibitors Y27632 and fasudil in ROCK
activity assay. KD025 also inhibited ROCK activity in
brain and heart when administered systemically, as
measured by the degree of MYPT1
Thr696 phosphoryla-
tion (Fig. 1C).
Pharmacokinetic proﬁle
To guide the dose and dose interval selection, we deter-
mined the pharmacokinetic proﬁle of KD025 in mice. We
administered the drug via orogastric gavage twice a day for
2 days and measured blood and brain tissue levels at prede-
termined time points starting immediately before the last
dose at 48 h (time 0; Fig. 2). We used both noncompart-
mental analysis, and zero and ﬁrst-order kinetic absorption
models for one-compartmental analysis (Table 2). Plasma
drug levels ﬁtted better to the ﬁrst-order absorption model
(R
2 = 0.98, Akaike Information Criterion [AIC] = 8.31),
whereas the brain drug levels ﬁtted better to zero order
absorption model (R
2 = 0.98, AIC = 6.52). Peak plasma
and brain concentrations were reached within 2 h of dos-
ing, and exceeded the in vitro IC50 by almost 10-fold. Brain
exposure was ~5% of plasma exposure based on brain/
plasma area under the concentration (AUC) ratio. Half-life
was shorter in the brain than plasma (2 vs. 5 h), presum-
ably due to the higher elimination constant, distribution
volume, and clearance rate for the brain. Observed mean
residence time was 4 and 7 h for brain and plasma, respec-
tively, suggesting that the compound did not accumulate in
the body at the dosing interval selected in this study (accu-
mulation factor [R] 1.15 and 1.02 for plasma and brain,
respectively). Nevertheless, 200 mg/kg dose level provided
sustained plasma and tissue concentrations for at least
12 h. Altogether, these data suggest that the selected dose
levels and twice a day dosing paradigm were appropriate to
test efﬁcacy and safety in ischemia models.
Dose-response relationship
In initial experiments to determine the optimal dose, we
started the treatment 24 h before 1 h transient fMCAO and
continued until sacriﬁce at 48 h (Fig. 3). We found a U-
shaped dose response relationship where 100 and 200 mg/
kg dose levels reduced infarct volume by 30% and 40%,
respectively. Efﬁcacy was partially lost at 300 mg/kg dose
level, and we observed increased incidence of vomiting and
respiratory difﬁculties presumably due to aspiration; these
animals were nevertheless included in the analyses. At the
optimal dose level of 200 mg/kg, infarct volume reduction
was most prominent at middle to posterior coronal slice
levels. Neurological deﬁcits, crudely assessed using the 5-
point scoring system prior to sacriﬁce, were also amelio-
rated. On the basis of these data, we used the optimal dose
of 200 mg/kg in all subsequent experiments.
Ischemic tissue perfusion
We have previously shown that isoform-nonselective
ROCK inhibition acutely augments perfusion in ischemic
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J. H. Lee et al. ROCK2 Inhibition in Focal Cerebral IschemiaFigure 2. Pharmacokinetic analysis. (A) KD025, 100 or 200 mg/kg, was administered (arrows) via oral gavage every 12 h for 48 h (ﬁve doses). Plasma
and tissue samples were collected at 0, 1, 2, 4, 6, 9, and 12 h after the last 100 mg/kg dose (triangles), and at 0, 1, and 9 h after the last 200 mg/kg
dose (circles) (n = 5 mice for each time point and dose level). Note that only a subset of time points was studied at the higher dose level. (B) Plasma
(circles) and brain tissue (squares) KD025 concentrations are shown at 100 mg/kg (left panel) or 200 mg/kg (right panel) dose levels. Mean  SEM.
Figure 1. ROCK1 versus ROCK2 selectivity, in vitro. (A) KD025 selectively inhibited ROCK2 over ROCK1, whereas isoform-nonselective Y27632
inhibited ROCK1 and ROCK2 to a similar extent in a recombinant enzyme system with truncated catalytic domains. IC50 values for each drug are
indicated on the graphs. (B) ROCK2 inhibition by KD025 was competitive with ATP. (C) Systemic administration of KD025 (200 mg/kg via oral
gavage 1 h before harvesting the tissues) inhibited ROCK activity in the brain, as well as in the heart, as measured by MYPT1 phosphorylation in
mice (n = 2 each vehicle and KD025). Total MYPT1 levels did not show a consistent change. The effect was comparable to that of isoform non-
selective ROCK inhibitor hydroxyfasudil (HF, 10 mg/kg, intraperitoneal).
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5 To test whether ROCK2 selective inhibitor KD025
shares this mechanism, we imaged the perfusion defect
during dMCAO using laser speckle ﬂowmetry noninva-
sively through intact skull. KD025 (200 mg/kg 90 min
before dMCAO) signiﬁcantly reduced the area of perfu-
sion defect when compared with vehicle-treated animals
(Fig. 4). These data suggest that selective ROCK2 inhibi-
tion improves cortical perfusion during acute cerebral
arterial occlusion, an effect shared with isoform-nonselec-
tive ROCK inhibitors.
Therapeutic window of postischemic
treatment
To determine the utility of KD025 as an acute stroke
intervention, we next tested whether KD025 is efﬁcacious
when administered as a postischemic treatment alone.
When administered starting 1 or 3 h after the onset of
fMCAO, KD025 (200 mg/kg) signiﬁcantly reduced infarct
volumes by 34% and 26%, respectively (Fig. 5). Efﬁcacy
was completely lost if the treatment was started 6 h after
ischemia onset. Therefore, the therapeutic window of efﬁ-
cacy was at least 3 h. In all subsequent experiments, we
tested the optimal efﬁcacy time point of 1 h after ische-
mia onset.
Long-term sustained efﬁcacy
We next tested in a separate group of mice whether
improved tissue outcome measured at 48 h was sustained
(Fig. 6). Because accurate histological demarcation of
infarcts at late time points is difﬁcult, we used tissue loss
and atrophy as an endpoint, calculated by measuring the
ipsilateral and contralateral hemispheric volumes. KD025
(200 mg/kg twice a day for 36 h starting 1 h after ische-
mia onset) signiﬁcantly reduced tissue loss in the ipsilat-
eral hemisphere compared with vehicle when measured
4 weeks after ischemia. These data suggest that the beneﬁ-
cial effect of KD025 on tissue outcome is sustained into
the subacute to chronic stage. Contralateral hemispheric
atrophy as well as the neurological deﬁcits also tended to
be milder in the KD025 group, although these did not
reach statistical signiﬁcance.
Efﬁcacy in female, aged, or diabetic animals
Successful translation of stroke therapeutics critically
depends on robust demonstration of efﬁcacy in all clini-
cally relevant cohorts. To this end, we tested KD025 in
female and aged male mice, as well as in a mouse model
of type 2 diabetes, a comorbid vascular risk factor com-
mon in stroke patients and associated with ROCK upreg-
ulation contributing to worse outcomes. Female mice
developed overall smaller infarcts (Fig. 7) compared with
males (see Figs. 3, 5). KD025 appeared even more efﬁca-
cious in females (42% reduction in infarct volume).
Infarct volumes in aged males (12 months; Fig. 7) were
comparable to young animals (see Figs. 3, 5). KD025
reduced infarct volume by 34% compared with vehicle in
aged mice. Type 2 diabetic db/db mice tended to develop
larger infarct volumes (Fig. 7) compared with age-
matched wild-type mice (Figs. 3, 5). KD025 reduced
infarct volumes by 32% compared with vehicle in diabetic
mice. These data suggest that KD025 maintains its efﬁcacy
in clinically relevant cohorts.
Safety in combination with statins
Statins inhibit ROCK signaling by reducing the synthesis
of isoprenyl intermediates of cholesterol metabolism that
are critical for Rho activation. This is believed to be
responsible, at least in part, for the pleiotropic actions of
statins. Therefore, KD025 may have additive or synergistic
interactions with statins that may potentially be unsafe.
We tested this in mice pretreated with atorvastatin
(20 mg/kg per day) for 2 weeks. KD025 was safe in ator-
vastatin-pretreated mice, but did not show an additive or
synergistic effect (Fig. 8A).
Table 2. Pharmacokinetic (PK) parameters at 100 mg/kg KD025 dose
level.
Plasma Brain
Non-compartmental analysis
AUCinf (h 9 lg/mL) 51.93 2.37
CL (L/h) 1.93 –
MRT (h) 6.81 4.17
V (L) 11.58 –
k2 (1/h) 0.16 0.31
T½ (h) 4.16 2.21
AUClast (h 9 lg/mL) 42.31 2.28
Tmax (h) 2 2
Cmax (lg/mL) 7.28 0.54
One-compartment ﬁrst-order kinetic absorption model
AUCinf (h 9 lg/mL) 44.83 2.05
CL (L/h) 2.23 –
V (L) 11.90 –
Ka (1/h) 2.23 –
Ke (1/h) 0.18 0.32
A (lg/mL) 9.16 0.67
T½ (h) 3.69 2.12
Tmax (h) 1.21 2
MRT (h) 5.78 3.06
AUC, area under the concentration versus time curve; AUCinf, AUC
until inﬁnity; CL, total body clearance; MRT, mean residence time; V,
volume of distribution; Ka, absorption rate constant; Ke, elimination
rate constant; A, absorption; k2, slope of the log-linear terminal
phase; T½, half-life; AUClast, AUC until last measurement time point;
Tmax, time to maximum concentration; Cmax, maximum concentration.
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Although most cerebral arterial occlusions eventually
recanalize, it is impossible to predict whether an occlu-
sion will remain permanent in the hyperacute stage. If the
drug were not safe in the absence of reperfusion, this
would preclude its hyperacute administration in the ﬁeld,
adding to the delay in treatment initiation until imaging
demonstration of recanalization. We, therefore, tested
the safety of KD025 in permanent fMCAO. Because the
model carries a high mortality over time, we assessed the
infarct volume at 24 h after ischemia onset to minimize
excess losses. As expected, infarct volumes were larger in
the permanent model (Fig. 8B) compared to transient
fMCAO (see Figs. 3, 5). KD025 was safe but lost its efﬁ-
cacy in the presence of persistent arterial occlusion.
Other safety endpoints
Hemorrhagic transformation, weight loss, and mortality
were recorded in all experiments. None of these safety
endpoints was signiﬁcantly altered by KD025 in any of
the experimental groups, except for increased weight loss
when it was combined with atorvastatin (Table 3; Fig.
S1). Because we did not have a sham group, it is unclear
whether this increased weight loss is directly related to
ischemia.
Systemic physiology
Previously tested isoform-nonselective inhibitors cause
hypotension that can be detrimental in acute stroke.
Therefore, we tested the systemic physiological effects of
Figure 3. Dose-response relationship. (A) Vehicle or KD025 was administered (arrows) every 12 h starting 24 h before the onset of 1 h transient
fMCAO and continued until sacriﬁce at 48 h (six doses). (B) Representative TTC-stained 1 mm-thick coronal brain slices show the infarct in
vehicle- or KD025-treated mice. (C) Infarct volumes (indirect method) were signiﬁcantly smaller after 100 or 200 mg/kg KD025 (n = 6 and 7,
respectively) compared with vehicle (n = 11). The effect was partially lost at 300 mg/kg dose level (n = 7). *P < 0.05 versus vehicle. Boxes,
median, and interquartile range; whiskers, min–max; +, mean. One-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Infarct
areas were smaller at middle and posterior coronal slice levels (1 mm-thick) in KD025 (200 mg/kg) group compared with vehicle (n = 7 and 11,
respectively). *P < 0.05 versus vehicle. Mean  SEM. Two-way ANOVA followed by Sidak’s multiple comparisons test. (E) Neurological deﬁcits
were milder in KD025-treated groups compared with vehicle when assessed at 48 h (see Methods for scoring system). *P < 0.05 versus vehicle.
Kruskal–Wallis test.
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in mice. Arterial blood pressures were only 8% lower in
KD025 group compared with vehicle (Table 4), suggesting
that the hypotensive effect of KD025 is much less potent
than the previously tested isoform-nonselective ROCK
inhibitors.
5 Other systemic physiological parameters did
not signiﬁcantly differ between the groups.
Discussion
These data implicate for the ﬁrst time ROCK2 as the rele-
vant isoform in acute stroke. We found the novel
ROCK2-selective small molecule inhibitor KD025 dose-
dependently safe and efﬁcacious in both males and
females, with a therapeutic window of at least 3 h. The
effect size was comparable to previously published iso-
form-nonselective inhibitors in similar animal mod-
els.
5,14,28 Improved tissue outcomes persisted for at least
4 weeks, and were maintained in aged and diabetic ani-
mals. Moreover, the drug was safe in combination with a
statin and in permanent ischemia, and unlike previously
tested inhibitors, did not cause severe hypotension. It is,
of course, possible that the dose-response and the thera-
peutic window, efﬁcacy on long-term outcome, and efﬁ-
cacy and safety in the permanent occlusion model may all
be different in females, in comorbid animal models, and
in combination with a statin. Unfortunately, testing all
variables in all animal cohorts is not a feasible approach,
and would have limited relevance in patient care, as the
efﬁcacy and safety proﬁle would have to be characterized
in clinical studies. Nevertheless, these data suggest that
KD025 holds promise for rapid clinical translation in
stroke. An intravenous formulation, if and when available,
may augment efﬁcacy by rapidly achieving therapeutic
plasma levels when administered in the hyperacute stage,
although its hypotensive effect may also be stronger and
dose-limiting.
Although ROCK2 is the main isoform expressed in the
brain, predominantly in neurons,
2,3,29,30 both isoforms are
also expressed in many other cell types relevant for acute
stroke pathophysiology.
2,3,30–39 For example, ROCK
Figure 4. Perfusion deﬁcit. (A) Vehicle or KD025 (200 mg/kg via
orogastric gavage) was administered (arrow) 90 min before dMCAO.
(B) Position of laser speckle imaging ﬁeld is shown covering the entire
right hemisphere. (C) Laser speckle blood ﬂow maps show
representative perfusion defects in vehicle- or KD025-treated mice.
Regions with <30% (light blue) or 31–40% (dark blue) residual blood
ﬂow are shown (see Methods for details). Clip artifact is seen on the
lower right of each image. (D) Area of cortical perfusion defect was
smaller in KD025 group compared with vehicle at all thresholding
levels (n = 5 each). *P < 0.05 versus vehicle. Boxes, median, and
interquartile range; whiskers, min–max. Two-way ANOVA followed by
Sidak’s multiple comparisons test.
Figure 5. Therapeutic window. (A) Vehicle or KD025 was
administered (arrows) starting 1, 3 or 6 h after fMCAO and continued
until sacriﬁce at 48 h (four doses). (B) Infarct volumes (indirect
method) are shown after postischemic vehicle or KD025 (200 mg/kg)
treatment starting 1, 3 or 6 h after dMCAO. KD025 was efﬁcacious
when administered 1 or 3 h but not 6 h after stroke onset (n = 8,
14, 7 vehicle, and 8, 15, 7 KD025, at 1 h, 3 h and 6 h time points,
respectively). *P < 0.05 versus vehicle. Boxes, median, and
interquartile range; whiskers, min–max; +, mean. Two-way ANOVA
followed by Sidak’s multiple comparisons test.
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ity,
40 and ROCK inhibitors acutely improve ischemic
tissue perfusion in an eNOS-dependent manner.
5,28
ROCK2-selective KD025 also improved ischemic tissue
perfusion in this study (Fig. 3), and has been shown to
mimic the effects of isoform-nonselective inhibitors in
endothelial migration assays,
41 suggesting that ROCK2 is
the main target isoform in endothelial cells. Moreover,
cerebral hypoxia and reoxygenation induces ROCK2
expression in microglia, and ROCK inhibitors suppress
microglial inﬂammatory response and ameliorate injury
in this model.
42 ROCK inhibition also suppresses leuko-
cyte inﬁltration after ischemia, although ROCK1 may be
the primary target for this effect.
15,43,44 In platelets,
ROCK promotes aggregation and thrombus contrac-
tion,
45,46 although not all studies agree.
13 Altogether, these
data suggest that ROCK is a pleiotropic target acting
through multiple independent mechanisms, and that
brain penetration may not be a prerequisite for ROCK
inhibitors to be neuroprotective in acute stroke. Never-
theless, our therapeutic paradigm achieved good brain tis-
sue levels and target activity, which may be further
enhanced upon ischemic blood–brain barrier disruption.
Hypotension is an important safety concern in acute
stroke. Isoform-nonselective ROCK inhibitors have acute
and potent hypotensive effects that can be dose-limiting
in acute stroke, particularly if complete reperfusion has
not been achieved.
5,47 KD025 induced only mild hypoten-
sion even at the maximally efﬁcacious dose level, suggest-
ing a more favorable safety proﬁle. Indeed, the absence of
hypotension probably allowed an even more potent
improvement in perfusion by KD025 compared with iso-
form-nonselective inhibitors.
5 Another potential safety
concern is platelet inhibition, although an antithrombotic
effect may in fact improve tissue perfusion in acute stroke
as an additional mechanism of protection. Our semi-
quantitative analysis did not detect an increase in the
incidence of hemorrhagic transformation in the transient
fMCAO model (Fig. S1), and ROCK inhibitors reportedly
ameliorated tPA-induced hemorrhagic transformation in
one study.
13
Therapeutic time window is another important consid-
eration in acute stroke therapy. Most if not all postis-
chemic interventions gradually lose their efﬁcacy as a
function of time between stroke onset and treatment. In
our studies, KD025 administered 1 h after stroke onset
was only marginally less efﬁcacious than 24 h preischem-
ic treatment. Indeed, the therapeutic window was
between 3 and 6 h, similar to tPA. While this is a rela-
tively short time window for treatments that require vig-
orous screening prior to instituting the treatment (e.g.,
tPA), a drug with a favorable safety proﬁle can easily be
administered in the ﬁeld thus markedly reducing the
Figure 6. Long-term tissue and neurological outcome. (A) Vehicle or
KD025 was administered (arrows) starting 1 h after fMCAO for a
total of four doses, followed by tissue outcome assessment at
4 weeks. (B) Representative hematoxylin/eosin-stained coronal
cryosections and ipsilateral and contralateral hemispheric volumes
show tissue loss and atrophy at 4 weeks after stroke in vehicle- or
KD025-treated mice (n = 6 and 9, respectively). Substantial atrophy
was present in ipsilateral hemisphere compared with contralateral.
KD025 reduced the amount of tissue loss. *P < 0.05 versus vehicle.
Boxes, median, and interquartile range; whiskers, min–max; +, mean.
Two-way ANOVA followed by Sidak’s multiple comparisons test. (C)
The improvement in neurological function, assessed by the time to
remove an adhesive tape from the contralateral forepaw, did not
reach statistical signiﬁcance between vehicle- and KD025-treated mice
(n = 17 each). Mean  SEM. Two-way ANOVA for repeated
measures.
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tion of stroke therapy-magnesium (FAST-MAG) trial,
where median treatment onset was 100 min after stroke
onset and 70% of patients received treatment within
2h .
48 KD025 showed no major side effects in one phase
I study in healthy volunteers (Surface Logix, Brighton,
MA), and the results of a subsequent extended dose
range phase I study (Kadmon Corporation, New York,
NY) are expected in the near future. It should also be
noted that KD025 required 1–2 h to reach the peak
plasma levels after oral administration, suggesting that its
therapeutic window for biological effect is even wider,
and that an intravenous formulation can achieve efﬁcacy
even at later time points.
Figure 7. Efﬁcacy in female, aged and diabetic mice. (A) Vehicle or KD025 administration (arrows) was started 1 h after fMCAO and continued
until tissue outcome assessment at 48 h (four doses). (B) Infarct volumes (indirect method) after vehicle or KD025 (200 mg/kg) in female (n = 9
each), aged (12 months; n = 6 each) and diabetic (db/db) mice (n = 6 and 8, respectively). One db/db mouse in the vehicle group was excluded
at the time of surgery due to technical failure. *P < 0.05 versus vehicle. Boxes, median, and interquartile range; whiskers, min–max; +, mean.
Unpaired t-test.
Figure 8. Safety in combination with atorvastatin and in permanent ischemia. (A) Daily atorvastatin treatment for 2 weeks was followed by
vehicle or KD025 administration (arrows) starting 1 h after fMCAO and continuing until sacriﬁce for tissue outcome assessment at 48 h (four
doses). (B) Infarct volumes (indirect method) after vehicle or KD025 (200 mg/kg) in combination with atorvastatin (n = 6 each). Boxes, median
and interquartile range; whiskers, min–max; +, mean. Unpaired t-test. (C) Timeline shows vehicle or KD025 administration (arrows) via oral
gavage starting 1 h after permanent fMCAO and continuing until tissue outcome assessment at 24 h (two doses). (D) Infarct volumes (indirect
method) in vehicle or KD025 (200 mg/kg) groups after permanent fMCAO (n = 10 and 9, respectively; P = 0.19). Boxes, median, and
interquartile range; whiskers, min–max; +, mean. Unpaired t-test.
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tor KD025 showed good efﬁcacy on cerebral ischemic
outcome in multiple experimental cohorts with a thera-
peutic window and safety proﬁle favorable for rapid clini-
cal translation. Future experiments will need to test safety
in a second species, and in embolic MCAO with or with-
out thrombolysis.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Hemorrhagic transformation. To perform a
semi-quantitative assessment of the incidence of hemor-
rhagic transformation, we developed a grading system
based on the following criteria: Grade 0, no hemorrhage;
Grade 1, single small hemorrhage; Grade 2, a single large,
or multiple small hemorrhages (arrowheads). Boxes, med-
ian, and interquartile range; whiskers, min–max; +, mean.
Mann–Whitney or Kruskal–Wallis test.
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